VAPrapid-2 is a randomised controlled trial that aims to test whether a rapid, biomaker-based exclusion of ventilator-associated pneumonia (VAP) can improve antibiotic stewardship for this group of patients.
Patients are recuited from 23 Intensive Care Units in the UK.
Chief Investigator: Professor John Simpson
Clinical Research Associate: Dr Tom Hellyer
Trial Manager: Jennie Parker
Funder: The Wellcome Trust and the Department of Health
Industry partner: Becton Dickinson Biosciences
Trial Registration: ISRCTN65937227